← FDA DRUG APPROVALS

FDA ANDA · ANDA090595

FLUVASTATIN SODIUM

fluvastatin

Sponsor: MYLAN PHARMS INC

APPLICATION
ANDA090595
TYPE
ANDA
ORIGINAL APPROVAL
2012-04-11
LATEST ACTION
2020-09-25
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

FLUVASTATIN SODIUMPrescription
FLUVASTATIN SODIUM EQ 40MG BASE · CAPSULE · ORAL
FLUVASTATIN SODIUMPrescription
FLUVASTATIN SODIUM EQ 20MG BASE · CAPSULE · ORAL

Approval history

2020-09-25Labeling · Supplement 7 · standardAP
2020-09-15Labeling · Supplement 3 · standardAP
2013-03-26Labeling · Supplement 2 · standardAP
2012-04-11OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →